Skip to main content
Darren Feldman, MD, Oncology, New York, NY, Memorial Sloan-Kettering Cancer Center

DarrenFeldmanMD

Oncology New York, NY

Genitourinary Oncology, Hematologic Oncology

Associate Attending, Memorial Sloan Kettering Cancer Center and Associate Professor of Medicine, Weill Cornell Medical College

Overview of Dr. Feldman

Dr. Darren Feldman is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from University of Maryland School of Medicine and has been in practice 15 years. He specializes in genitourinary oncology and hematologic oncology and is experienced in testicular neoplasms, kidney cancer, and urologic oncology

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology/Oncology, 2005 - 2008
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterChief Residency, Internal Medicine, 2004 - 2005
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineInternship, Internal Medicine, 2001 - 2004
  • University of Maryland School of Medicine
    University of Maryland School of MedicineClass of 2001

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2020 - Present
  • NJ State Medical License
    NJ State Medical License 2019 - 2023
  • NY State Medical License
    NY State Medical License 2004 - 2023
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...  
    Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer

Lectures

  • Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for in... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patien... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

  • Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
  • Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018

Press Mentions

  • Phase 3 Trial Compares Standard-Dose Versus High-Dose Combination Chemo with Stem Cell Transplant for Germ Cell Tumors
    Phase 3 Trial Compares Standard-Dose Versus High-Dose Combination Chemo with Stem Cell Transplant for Germ Cell TumorsJune 25th, 2019
  • International Collaboration Studies Teratoma with Malignant Transformations Dismal Outcomes
    International Collaboration Studies Teratoma with Malignant Transformations Dismal OutcomesFebruary 28th, 2015
  • Cabozantinib Improves Quality-Adjusted Survival in Advanced RCC
    Cabozantinib Improves Quality-Adjusted Survival in Advanced RCCOctober 23rd, 2020

Hospital Affiliations